AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook
1. AstraZeneca's Q2 2025 sales rose 12% to $14.46 billion, beating estimates. 2. Oncology sales, notably Tagrisso and Imfinzi, drove significant revenue growth. 3. FDA granted Priority Review for Imfinzi in gastric cancer, enhancing market potential. 4. Total revenue for 2025 projected to rise by high single digits. 5. Stock rose 2.60% in premarket, indicating positive market reception.